Roche currently has several different therapeutic antibody technologies in early clinical development which in the future could hopefully be a strong pillar in addressing the complexity of targeting more than 250 cancer diseases.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
No comment yet.
Sign up to comment
|
Krishan Maggon 's curator insight,
April 15, 2015 2:32 AM
REVIEW Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion ProteinsLiming Liu*Article first published online: 14 APR 2015 DOI: 10.1002/jps.24444 © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association Issue Journal of Pharmaceutical SciencesEarly View (Online Version of Record published before inclusion in an issue) |